05 October 2016

Bayer Indonesia supports the Indonesian Heart Rhythm Society (InaHRS) in their 4th annual meeting in Jakarta and the organization’s effort to increase competencies in diagnosing arrhythmia in order to

  • Bayer supports InaHRS during their 4th Annual Scientific Meeting Indonesian Heart Rhythm Society, 7 to 8 October 2016, which will be attended by one thousand participating medical doctors and speakers from Indonesia as well as abroad.
  • Main topic of the InaHRS 4th annual scientific meeting focuses on enhancing competence in arrhythmias diagnosis to reduce Sudden Cardiac Deaths (SCD).
  • More than seven million lives are estimated to be lost to Sudden Cardiac Deaths per year1.

Jakarta, 5 Oktober 2016
As the Life Science company in Indonesia, Bayer supports the Indonesian Heart Rhythm Society (InaHRS) in their effort to increase the knowledge and enhance the competence of medical doctors in Indonesia through their a scientific meeting in Jakarta from 7 to 8 October with the main topic of “Enhance Arrhythmias Diagnosis Reduce Sudden Cardiac Death”.

More than seven million lives are estimated to be lost to Sudden Cardiac Deaths or SCD per year2. The changing dietary and lifestyle habit in developing nations is leading to a trend towards increasing incidence of SCD3. One of the causes is Arrythmia. An arrhythmia is a problem with the rate or rhythm of your heartbeat. It means that your heart beats too quickly, too slowly, or with an irregular pattern. Arrhythmias must be properly diagnosed because they can lead to stroke or SCD. This year’s InaHRS scientific meeting will provide much needed updates on key topics related to Arrhythmias such as SCD, Atrial Fibrillation, Syncope, Heart Failure and Arrhythmias, Device Therapy, VT-SVT dan Pediatric Arrhythmia.

President Director of Bayer Indonesia, Ashraf Al-Ouf stated, “As a Life Science company, Bayer is committed in supporting scientific meetings for medical doctors. Globally Bayer collaborates with institutions in the field of research and clinical studies so that we can help medical doctors obtain the latest therapy for their patients and in return, their patients will be able to receive the best possible medicine and medical services. Towards this end, we fully support InaHRS in their annual scientific meeting this year. I am certain that this meeting will bring much needed information for the medical community in Indonesia especially for diagnosing arrhythmia so that the number of related SDC can be reduced. What InaHRS is doing is in line with Bayer’s mission, which is to use our science in order to help people to be able to have a better quality of life. Last year alone we invested IDR 41.3 trillion for our R&D in health care as we seek solutions to the challenges of our times globally. Our newly launched products aim to help patients who suffer from cancer, stroke, thrombosis and age-related eye diseases. We shall continue to seek new medical solutions to bring innovative new medicines for people around the world, including Indonesia”

The world’s population is fast expanding and aging. Accounting for more than half of the world's population, Asia / Pacific will add close to 580 million people by 2050. The region is at the same time experiencing aging at an unprecedented rate – the percentage of older persons aged 60 years and above is set to double from 12 percent to 24 percent by 20504, while confronting an increase in medical conditions like cancer, cardiovascular diseases and diabetes.

In the Asia Pacific region, cardiovascular diseases will remain a key area of medical need. Mirroring the burden imposed globally, cardiovascular diseases have been a leading cause of death in the region, accounting for 8.2 million cases of mortality in 2015. This is an increase of 21% from 6.8 million in 20055.

Atrial Fibrillation or AF is one of the cardiovascular diseases. Heart failure and stroke are some of the complications that may be caused by AF which may also lead to serious or permanent disability. Although the number is higher with among the elderlies, this disease remains significant for the younger population.

Data from an observational study (MONICA – multinational MONItoring of trend and determinant in Cardiovascular disease), shows that AF is on the rise in Jakarta alone where current numbers indicate that AF affects 0.2% of the total population of this city with a ratio of 3 men to 2 women6. Additionally, WHO data projects a significant increase in elderly population in Indonesia from 7.74% (in 2000 to 2005) to 26.68% (in 2045 to 2050)7, thus potentially increasing the FA numbers, as well. Meanwhile data from Rumah Sakit Harapan Kita in Jakarta shows a steady increase in the number of patients suffering from AF, from 7.1% in 2010, 9% in 2011, 9.3% in 2012 to 9.8% in 2013.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

Media Contact:
Anton Susanto
Head of Communications
PT Bayer Indonesia
Phone: +62-21-30491506
E-mail: anton.susanto@bayer.com

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

 

Reference:

  1. Myerburg, R.J. (2001) Sudden Cardiac Death: Exploring the Limits of Our Knowledge. Journal of Cardiovascular Electrophysiology, 12, 369. http://dx.doi.org/10.1046/j.1540-8167.2001.00369.x
  2. American Heart Association: 2015 Heart Disease and Stroke Statistics Update
  3. Mehra, R. (2007) Global Public Health Problem of Sudden Cardiac Death. Journal of Electrocardiology, 40, S118- S122. http://dx.doi.org/10.1016/j.jelectrocard.2007.06.023
  4. United Nations Department of Economic and Social Affairs/Population Division World Population Prospects: The 2015 Revision, Key Findings and Advance Tables.
  5. Asia - Differentiated Products Needed To Leverage The Cardiovascular Disease Segment. BMI research report, February 12, 2016 .
  6. Setianto B, Malik MS, Supari SF. Studi aritmia pada survei dasar MONICA-Jakarta di Jakarta Selatan. Badan Penelitian dan Pengembangan Kesehatan Depkes RI 1998.
  7. RI PDdIKK. Gambaran kesehatan usia lanjut di Indonesia. Buletin Jendela Data dan Informasi Kesehatan 2013